Sclerostin has been recognized as a negative regulator of bone formation through inhibition of canonical Wnt signaling pathway in osteoblast lineage cells [2], and its role was first recognized in the study of two rare high bone mass disorders, namely sclerosteosis [3] and van Buchem’s disease [4]. This evidence concerns the gene SOST and sclerosteosis.